OncoMatch/Clinical Trials/NCT06953089
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Is NCT06953089 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including DB-1311/BNT324 and BNT327 for solid tumors.
Treatment: DB-1311/BNT324 · BNT327 · DB-1305/BNT325 — A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Hepatocellular Carcinoma
Cervical Cancer
Melanoma
Ovarian Cancer
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Breast Carcinoma
Triple-Negative Breast Cancer
Colorectal Cancer
Prostate Cancer
Biomarker criteria
Required: EGFR sensitizing mutation
Not harboring an EGFR-sensitizing mutation or ALK gene rearrangements or other onco-driver gene mutations
Required: ALK rearrangement
Not harboring an EGFR-sensitizing mutation or ALK gene rearrangements or other onco-driver gene mutations
Disease stage
Metastatic disease required
At least one measurable lesion as assessed by the Investigator according to RECIST v1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: B7H3 targeted therapy
Prior treatment with B7H3 targeted therapy
Cannot have received: antibody-drug conjugate with topoisomerase inhibitor
Prior treatment with antibody-drug conjugate with topoisomerase inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USA06-0 · Los Angeles, California
- USA16-0 · Los Angeles, California
- USA01-0 · Wheat Ridge, Colorado
- USA08-0 · Florida City, Florida
- USA10-0 · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06953089 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7H3 targeted therapy, antibody-drug conjugate with topoisomerase inhibitor disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify